Financial year 2025/26

Ypsomed reached a decisive milestone in the past financial year, laying the foundation for the next phase of growth. The sale of the Diabetes Care business and Ypsotec successfully completed the transformation into a pure-play injection specialist. As a pure-play provider of injection systems, we are now fully focused on a clearly defined, high-growth market and are aligning our business accordingly.